TWYNEO
Peaktretinoin and benzoyl peroxide
NDATOPICALCREAM
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TWYNEO is a fixed-dose combination topical cream containing tretinoin (a retinoid) and benzoyl peroxide, approved in 2021 for the treatment of acne. The combination leverages tretinoin's keratolytic and anti-inflammatory properties alongside benzoyl peroxide's antimicrobial action to address acne pathogenesis. This dual mechanism in a single formulation simplifies patient regimens compared to sequential or separate applications.
$0.052MPart D
Peak15.0 years to LOEPeak-stage product with minimal Part D penetration suggests limited market adoption or narrow payer coverage; brand team likely focused on access expansion and prescriber education.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TWYNEO roles focus on commercial execution in a mature dermatology segment with low current job velocity; career advancement requires strong payer negotiation, prescriber education, and market-share growth skills. The 15-year patent runway offers job security and mid-career stability, though limited clinical expansion means career progression may be lateral rather than vertical.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.